Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of enzalutamide for participants with prostate cancer previously treated in an enzalutamide clinical study
2023-510298-33-00Phase 2Authorised
- Sponsor
- Astellas Pharma
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Planned start Nov 2016; status: authorised.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-510298-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510298-33-00.